成都先导药物开发股份有限公司 股东深圳市钧天投资企业（有限合伙）减持股份结果公告

Summary of Key Points Core Viewpoint - The announcement details the shareholding and reduction plan of Chengdu XianDao Pharmaceutical Development Co., Ltd., specifically regarding the share reduction by its shareholder Shenzhen JunTian Investment Enterprise (Limited Partnership) Group 1: Shareholding Information - Before the reduction plan, Shenzhen JunTian held 11,927,164 shares, accounting for 2.98% of the company's total share capital, with these shares being tradable since April 16, 2021 [1] Group 2: Reduction Plan Implementation - On August 5, 2025, the company disclosed a plan for Shenzhen JunTian to reduce its holdings by 2,000,000 shares, representing approximately 0.50% of the total share capital, to be executed within three months starting from August 8, 2025 [1] - By November 7, 2025, Shenzhen JunTian had reduced its holdings by 1,859,413 shares, which is 0.46% of the total share capital, leaving it with 10,067,751 shares, or 2.51% of the total [2] Group 3: Compliance and Results - The actual reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [4]